Share

    


Home / Search Results

Search Results

You searched for:

Hear about the evolution of artificial intelligence in precision oncology and the clinical impact of tech-based solutions.
CANCER BUZZ previews the sessions, people and topics of this week’s ACCC 40th National Oncology Conference. We interview Kathy Oubre, MS, CEO of the Pontchartrain Canter Center, about helping patients overcome access barriers to biomarker testing.
It is important for the cancer team to be able to recognize what a small cell might look like — such as central location of the tumor, bulky adenopathy generally.
To standardize comprehensive biomarker testing in patients with NSCLC, Oncology Hematology Care, Inc., developed and implemented a 1-year quality improvement (QI) project that included custom data reports and monitoring dashboards to ensure practice-wide adoption and sustainability across multiple clinic sites.
In this episode, hear about the fully remote TRACK (Target Rare Cancer Knowledge) clinical trial and its unique approach to providing access to biomarker testing for patients in community care settings by leveraging technology.
CANCER BUZZ speaks with Susan Spinosa, president and patient founder of NTRKers, an organization created to support patients with NTRK fusion-positive cancer, about her care journey and the importance of testing for NTRK gene fusions.
Stephen Quake, PhD, spoke to CANCER BUZZ about the application of liquid biopsies across multiple cancer stages and their potential to improve patient outcomes, minimize financial toxicity, and create health equity through greater testing access and lower cost.
Precision medicine is increasingly critical to selecting the right treatment for patients with cancer, but pathology reporting can be lengthy, complex, and confusing—especially in this fast-paced molecular era. Hear one provider’s suggestions for simplifying and standardizing pathology reports so patients can be better informed, understand their prognosis, and own the progress of their therapies.
Presented at the 63rd ASH Annual Meeting, December 11-14, 2021, in Atlanta, GA.
Biomarker testing is crucial to precision medicine, but barriers still exist. Learn from two healthcare advocates about recent policy changes designed to ensure better access to biomarker testing.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.